Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies
Part of paid clinical trials in Albuquerque, New Mexico.
- Sponsor
- New Mexico Cancer Research Alliance
- Study ID
- NCT03943316
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
Ascites samples from women undergoing surgery for ovarian cancer will be collected for use in translational research.
Key Dates
- Start date
- Dec 2, 2015
- Status verified
- May 2025
- Primary completion
- Dec 31, 2025
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 100 participants (estimated)
Primary Outcome Measure
Collect ascites fluid obtained from ovarian cancer patients during cytoreductive surgery or paracentesis [ Time Frame: 5 years ]
Central Contacts
- Sarah Adams, MD(505) 925-0461
- Amy Overby505-272-5557
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of New Mexico Cancer Center | Albuquerque | New Mexico | 87131 | Sharareh Sazesh, MS Sarah Adams, MD (PRINCIPAL_INVESTIGATOR) Carolyn Muller, MD (SUB_INVESTIGATOR) Bridget Wilson, PhD (SUB_INVESTIGATOR) Laurie Hudson, PhD (SUB_INVESTIGATOR) Angela Wandinger-Ness, PhD (SUB_INVESTIGATOR) Helen Hathaway, PhD (SUB_INVESTIGATOR) Eric Prossnitz, PhD (SUB_INVESTIGATOR) Mara Steinkamp, PhD (SUB_INVESTIGATOR) Sabrina Samudio-Ruiz, PhD (SUB_INVESTIGATOR) |
Find similar trials in Albuquerque, NM
By condition
By specialty
By research site
Related Studies
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesPHASE1/PHASE2 · Recruiting · AstraZeneca · Duarte, California
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)PHASE2 · Recruiting · AstraZeneca · Los Angeles, California
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)PHASE3 · Recruiting · Merck Sharp & Dohme LLC · Birmingham, Alabama